Epidemiological Characteristics of Meningococcal Meningitis (2016 to 2018) Four Years after the Introduction of Serogroup A Meningococcal Conjugate Vaccine in Benin

被引:1
|
作者
Godjedo, Togbemabou Primous Martial [1 ,2 ]
Agbankpe, Alidehou Jerrold [3 ]
Paraiso, Moussiliou Noel [4 ]
Dougnon, Tamegnon Victorien [3 ]
Hidjo, Marie [3 ]
Baba-Moussa, Lamine [5 ]
Bankole, Honore [1 ,3 ]
机构
[1] Minist Publ Hlth, Epidmiol Surveillance Serv, Cotonou, Benin
[2] Minist Publ Hlth, Natl Hlth Lab, Cotonou, Benin
[3] Univ Abomey Calavi, Res Lab Appl Biol, Polytech Sch Abomey Calavi, Res Unit Appl Microbiol & Pharmacol Nat Subst, Cotonou, Benin
[4] Univ Abomey Calavi, Reg Inst Publ Hlth, Cotonou, Benin
[5] Univ Abomey Calavi, Lab Biol & Mol Typing Microbiol, Fac Sci & Technol, Cotonou, Benin
来源
ADVANCES IN PUBLIC HEALTH | 2020年 / 2020卷
关键词
BACTERIAL-MENINGITIS; COUNTRIES; BELT; SURVEILLANCE; AFRICA;
D O I
10.1155/2020/1932940
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives. This study aims to study the epidemiological and geographic characteristics of the meningococcal serogroups four years after the introduction of serogroup A meningococcal conjugate vaccine.Methods. This is a prospective, descriptive, analytical study, and it took place from 2016 to 2018. Cerebrospinal fluid (CSF) samples were taken after the identification of meningitis cases. The samples, thus, taken were sent to the laboratory for culture and identification ofNeisseria meningitidisin accordance with WHO standards.Results. Eight hundred and ninety-nine bacterial strains were identified, of which 219 were strains ofNeisseria meningitidis. The majority ofN. meningitidis-positive samples were from male patients (59.8%) with a median age of 4 (IQR: 1-13). Four ofN. meningitidisserogroups were identified, namely, serogroups C (6.8%), W (19.6%), X (1.8%), and A (0.5%). Geographically, 92.7% of the identifiedN. meningitidisserogroups came from patients who lived in the northern region of the country. The departments most concerned were Alibori (N. meningitidisC (66.7%) andN. meningitidisW (20.9%)); Atacora (N. meningitidisW (41.9%),N. meningitidisX (75.0%), andN. meningitidisC (13.3%)); and Borgou (N. meningitidisW (23.3%)).Conclusion. The results of this study showed that there is an emergence of cases of meningococcal of serogroup C four years after the introduction of MenAfricVac in Benin. These results demonstrated the effectiveness of case-by-case surveillance in detecting small changes in the distribution of serogroups that could have important implications for public health strategies in the coming seasons.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] IMPACT OF MENINGOCOCCAL SEROGROUP A CONJUGATE VACCINE ON MENINGITIS EPIDEMIOLOGY-BURKINA FASO, 2011-2015
    Diallo, Alpha Oumar
    Soeters, Heidi M.
    Yameogo, Issaka
    Sawadogo, Guetawende
    Ake, Flavien
    Wang, Xin
    Sangare, Lassana
    Ouedraogo-Traore, Rasmata
    Medah, Isaie
    Bicaba, Brice
    Novak, Ryan T.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 235 - 235
  • [22] Changing epidemiology of Infant Meningococcal Disease after the introduction of meningococcal serogroup C vaccine in Italy, 2006-2014
    Stefanelli, P.
    Fazio, C.
    Neri, A.
    Boros, S.
    Renna, G.
    Pompa, M. G.
    VACCINE, 2015, 33 (31) : 3678 - 3681
  • [23] Meningococcal serogroup A and tetanus immunity two years after MenAfriVac™ introduction in Mali
    Basta, N. E.
    Ng, S.
    Berthe, A.
    Bai, X.
    Findlow, H.
    Almond, R.
    Borrow, R.
    Sow, S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 435 - 435
  • [24] Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine
    de Voer, Richarda M.
    Mollema, Liesbeth
    Schepp, Rutger M.
    de Greeff, Sabine C.
    van Gageldonk, Pieter G. M.
    de Melker, Hester E.
    Sanders, Elisabeth A. M.
    Berbers, Guy A. M.
    van der Klis, Fiona R. M.
    PLOS ONE, 2010, 5 (08):
  • [25] Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac
    Kristiansen, Paul A.
    Ba, Absatou Ky
    Ouedraogo, Abdoul-Salam
    Sanou, Idrissa
    Ouedraogo, Rasmata
    Sangare, Lassana
    Diomande, Fabien
    Kandolo, Denis
    Saga, Inger Marie
    Misegades, Lara
    Clark, Thomas A.
    Preziosi, Marie-Pierre
    Caugant, Dominique A.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [26] Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, Wand Y conjugate vaccine
    van Ravenhorst, Mariette B.
    den Hartog, Gerco
    van der Klis, Fiona R. M.
    van Rooijen, Debbie M.
    Sanders, Elisabeth A. M.
    Berbers, Guy A. M.
    PLOS ONE, 2018, 13 (04):
  • [27] Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease
    Souza, Alessandra R.
    Maruyama, Claudia M.
    Safadi, Marco Aurelio P.
    Lopes, Marta H.
    Azevedo, Raymundo S.
    Findlow, Helen
    Bai, Xilian
    Borrow, Ray
    Weckx, Lily Y.
    VACCINE, 2016, 34 (36) : 4327 - 4334
  • [28] Impact of meningococcal C conjugate vaccination four years after introduction of routine childhood immunization in Brazil
    Andrade, Ana Lucia
    Minamisava, Ruth
    Tomich, Lisia Moura
    Lemos, Ana Paula
    Gorla, Maria Cecilia
    de Cunto Brandileone, Maria Cristina
    Domingues, Carla Madga S.
    de Moraes, Camile
    Policena, Gabriela
    Bierrenbach, Ana Luiza
    VACCINE, 2017, 35 (16) : 2025 - 2033
  • [29] Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018
    Aksnes, Brooke Noel
    Walldorf, Jenny A.
    Nkwenkeu, Sylvain F.
    Zoma, Robert L.
    Mirza, Imran
    Tarbangdo, Felix
    Fall, Soukeynatou
    Hien, Sansan
    Ky, Cesaire
    Kambou, Ludovic
    Diallo, Alpha Oumar
    Ake, Flavien H.
    Hatcher, Cynthia
    Patel, Jaymin C.
    Novak, Ryan T.
    Hyde, Terri B.
    Medah, Isaie
    Soeters, Heidi M.
    Jalloh, Mohamed F.
    VACCINE, 2021, 39 (43) : 6370 - 6377
  • [30] Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines
    Vesikari, Timo
    Forsten, Aino
    Bianco, Veronique
    Van der Wielen, Marie
    Miller, Jacqueline M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (12) : E298 - E307